References
- Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006; 12:178–207.
- Bryant SG, Guernsey BG, Ingrim NB. Review of bupropion. Clin Pharm 1983; 2:525–537.
- Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol 2014; 69:513–551.
- WELBUTRIN label information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018644s046s047lbl.pdf. Accessed on 24th March 2014.
- WELBUTRIN SR label information: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020358s053s054lbl.pdf. Accessed on 24th March 2014.
- WELBUTRIN XL label information: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021515s026s027lbl.pdf. Accessed on 24th March 2014.
- Azzaro AJ, Ward HE. Drugs used in mood disorders. In: Craig CR, Stitzel RE, eds. Modern Pharmacology, 4th ed. Boston: Little, Brown; 1990:397–411.
- Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry SE, Kunkel S. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med 2009; 27:911–915.
- Caillier B, Pilote S, Castonguay A, Patoine D, Ménard-Desrosiers V, Vigneault P, et al. QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile. Fundam Clin Pharmacol 2012; 26:599–608.
- Druteika D, Zed PJ. Cardiotoxicity following bupropion overdose. Ann Pharmacother 2002; 36:1791–1795.
- Vento AE, Schifano F, Gentili F, Pompei F, Corkery JM, Kotzalidis GD, Girardi P. Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. Ann 1st Super Sanita 2013; 49:402–405.
- McCormick J. Recreational bupropion abuse in a teenager. Br J Clin Pharmacol 2002; 53:214.
- Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methyphenidate, bupropion, and triazolam in D-amphetamine-trained humans. Exp Clin Psychopharmacol 1998; 6:32–44.
- Reeves RR, Ladner ME. Additional evidence of the abuse potential of bupropion. J Clin Psychopharmacol 2013; 33:584–585.
- Hill S, Sikand H, Lee J. A case report of seizure induced by bupropion nasal insufflation. Prim Care Companion J Clin Psychiatry 2007; 9:67–69.
- Yoon G, Westermeyer J. Intranasal bupropion abuse: case report. Am J Addict. 2013; 22:180.
- Hilliard WT, Barloon L, Farley P, Penn JV, Koranek A. Bupropion diversion and misuse in the correctional facility. J Correct Health Care 2013; 19:211–217.
- Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM 2010; 12: 158–161.
- Baribeau D, Araki KF. Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent. J Addict Med 2013; 7:216–217.
- Welsh CJ, Doyon S. Seizure induced by insufflation of bupropion. N Engl J Med 2002; 347:951.
- Khurshid KA, Decker DH. Bupropion insufflation in a teenager. J Child Adolesc Psychopharmacol. 2004; 14:157–158.
- Bronstein AC, Spyker DA, Cantilena LR, Green JL, Rumack BH, Heard SE. 2007 Annual report of the American association of poison control centers’ national poison data system (NPDS): 25th annual report. Clin Toxicol (Phila) 2008; 46:927–1057.
- American Association of Poison Control Centers (AAPCC): National Poison Data System (NPDS) NPDS Coding Users’ Manual. 2014. (Internal Document).
- Langguth B, Hajak G, Landgrebe M, Unglaub W. Abuse potential of bupropion nasal insufflation: a case report. J Clin Psychopharmacol. 2009; 29:618–619.
- Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. CMAJ 2014; 186:1015.
- Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry SE, Kunkel S. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med 2009; 27:911–915.
- Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50:256–261.
- Preskorn SH. Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry 1983; 44:137–139.